Semaglutide

About the Product

Genetic Labs Semaglutide is a high-purity synthetic peptide (research grade) supplied in a vial containing 5mg of lyophilized (freeze-dried) powder. Semaglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1) hormone, engineered for enhanced stability and extended duration of action. It functions as a potent and selective GLP-1 receptor agonist, making it a valuable tool for research in metabolism, endocrinology, and neurobiology.

Kit Contents:

• 1 Vial with 5mg Semaglutide (Lyophilized Powder)

• 1 Vial with Bacteriostatic Water (Diluent)

For Laboratory Research Use Only. Not for human consumption.

Benefits (Research Scope)

• GLP-1 Receptor Agonist: Semaglutide selectively binds to and activates the GLP-1 receptor (GLP-1R), a key regulator of glucose homeostasis, insulin secretion, appetite, and gastric emptying. Its prolonged half-life makes it particularly suitable for studying sustained GLP-1 receptor activation.

• Versatile Research Tool: Suitable for a wide range of studies, including:

  • Metabolic Disorders: Research into type 2 diabetes, obesity, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD).

  • Appetite & Energy Balance: Studies on hypothalamic regulation of food intake, satiety signaling, and body weight control.

  • Neuroendocrinology: Investigation into the role of GLP-1 in the central nervous system, including neuroprotection, cognitive function, and reward pathways.

  • Cardiovascular Research: Studies on the cardioprotective effects of GLP-1 receptor agonists, including blood pressure regulation, endothelial function, and cardiac metabolism.

  • Gastrointestinal Research: Research into gastric motility, gastric emptying, and enteric nervous system function.

  • Renal Research: Studies on the protective effects of GLP-1 agonists on kidney function in models of diabetic nephropathy.

• Practical Formulation: The lyophilized powder ensures stability and extended shelf life, while the included bacteriostatic water facilitates easy reconstitution for both in vitro and in vivo experiments.

Research & Science

Semaglutide is one of the most extensively studied GLP-1 receptor agonists, with a robust body of preclinical and clinical research supporting its mechanism and broad therapeutic potential.

• Mechanism of Action: Semaglutide is a 31-amino-acid peptide analog of human GLP-1. It binds to the GLP-1 receptor (GLP-1R) on pancreatic beta cells, activating the cAMP-dependent signaling pathway, which leads to:

  • Glucose-dependent insulin secretion: Insulin release is stimulated only when blood glucose levels are elevated, minimizing the risk of hypoglycemia.

  • Suppression of glucagon secretion: Reduces hepatic glucose production.

  • Slowing of gastric emptying: Delays nutrient absorption, contributing to postprandial glucose control.

  • Appetite suppression: Acts on hypothalamic GLP-1 receptors to reduce food intake and promote satiety.

  • Weight loss: Promotes sustained weight reduction through a combination of central and peripheral mechanisms.

• Extended Duration: Semaglutide's structure includes a fatty acid side chain (C18) that facilitates albumin binding, resulting in a prolonged half-life of approximately 7 days, making it suitable for once-weekly dosing in clinical studies.

• Metabolic Research: Preclinical studies have demonstrated that semaglutide:

  • Significantly reduces body weight and adiposity in diet-induced obesity models.

  • Improves glycemic control and insulin sensitivity.

  • Reduces hepatic steatosis and liver inflammation in NAFLD models.

  • Improves lipid profiles with reductions in triglycerides and LDL cholesterol.

• Cardiovascular Research: Semaglutide has been shown to improve cardiovascular outcomes in clinical trials, including reduced risk of major adverse cardiovascular events (MACE), making it a key compound for research into cardiometabolic health.

• Neuroprotective Research: Emerging research is exploring semaglutide's potential in neurodegenerative diseases. GLP-1 receptors are expressed in the brain, and studies have shown that semaglutide may reduce neuroinflammation, improve cognitive function, and protect against neuronal death in models of Alzheimer's disease and Parkinson's disease.

• Renal Research: Semaglutide has demonstrated reno-protective effects, including reduced albuminuria and preservation of kidney function in models of diabetic nephropathy.

• Focus on Genetic Variability: Current research is investigating how genetic polymorphisms in the GLP-1 receptor gene (GLP1R) and other metabolic pathway genes may influence individual responses to semaglutide, providing insights for personalized metabolic interventions.